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Differential effects of short- and long-term antipsychotic treatment on the 
expression of neuregulin-1 and ErbB4 receptors in the rat brain 
Abstract 
Neuregulin-1 (NRG1) and ErbB4 genes have been identified as candidate genes for schizophrenia. Post-
mortem studies indicated that NRG1-ErbB4 signalling is impaired in schizophrenia subjects. This study 
investigated whether short- or long-term antipsychotic treatment has different effects on the expression 
of NRG1 and ErbB4 receptors. Female Sprague-Dawley rats were treated orally with either aripiprazole 
(0.75 mg/kg), haloperidol (0.1 mg/kg), olanzapine (0.5 mg/kg), or vehicle, 3 times/day for 1 or 12 weeks. 
Western blotting was performed to examine the expression of NRG1 isoforms (135 kDa, 70 kDa and 40 
kDa) and ErbB4 receptors. Both 1-week haloperidol and olanzapine treatment increased NRG1-70 kDa 
expression in the hippocampus; haloperidol also up-regulated ErbB4 levels in the prefrontal cortex (PFC). 
In the 12-week group, aripiprazole decreased the expression of all three NRG1 isoforms and ErbB4 
receptors in the PFC, NRG1-70 kDa and -40 kDa in the cingulate cortex (Cg), and NRG1-135 kDa, -70 kDa 
and ErbB4 receptors in the hippocampus; haloperidol reduced NRG1-135 kDa in the PFC, NRG1-40 kDa in 
all three brain regions, and ErbB4 receptor levels in the PFC and hippocampus; NRG1-40 kDa in the PFC 
and Cg was also down-regulated by olanzapine. These results suggest that the time-dependent and 
region-specific effects of antipsychotics on NRG1-ErbB4 signalling may contribute to the efficacy of 
antipsychotics to treat schizophrenia. 
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Neuregulin-1 (NRG1) and ErbB4 genes have been identified as candidate genes for 
schizophrenia. Post-mortem studies indicated that NRG1-ErbB4 signalling is impaired in 
schizophrenia subjects. This study investigated whether short- or long-term antipsychotic 
treatment has different effects on the expression of NRG1 and ErbB4 receptors. Female 
Sprague-Dawley rats were treated orally with either aripiprazole (0.75mg/kg), haloperidol 
(0.1mg/kg), olanzapine (0.5mg/kg), or vehicle, 3 times/day for 1 or 12 weeks. Western 
blotting was performed to examine the expression of NRG1 isoforms (135kDa, 70kDa and 
40kDa) and ErbB4 receptors. Both 1-week haloperidol and olanzapine treatment increased 
NRG1-70kDa expression in the hippocampus; haloperidol also up-regulated ErbB4 levels in 
the prefrontal cortex (PFC). In the 12-week group, aripiprazole decreased the expression of 
all three NRG1 isoforms and ErbB4 receptors in the PFC, NRG1-70kDa and -40kDa in the 
cingulate cortex (Cg), and NRG1-135kDa, -70kDa and ErbB4 receptors in the hippocampus; 
haloperidol reduced NRG1-135kDa in the PFC, NRG1-40kDa in all three brain regions, and 
ErbB4 receptor levels in the PFC and hippocampus; NRG1-40kDa in the PFC and Cg was 
also down-regulated by olanzapine. These results suggest that the time-dependent and region-
specific effects of antipsychotics on NRG1-ErbB4 signalling may contribute to the efficacy 
of antipsychotics to treat schizophrenia. 
 










Neuregulin-1 (NRG1) is a family of membrane-anchored proteins containing an epidermal 
growth factor (EGF)-like domain that signals by stimulating membrane-associated tyrosine 
kinases, including ErbB4 receptors (Harrison and Law, 2006; Mei and Xiong, 2008). NRG1-
induced stimulation of the ErbB4 receptor activates several signalling pathways that are 
involved in multiple biological functions in neurodevelopment, including neuronal 
specification, neuronal migration, neuronal development, and plasticity of the adult brain 
(Geddes et al., 2011; Mei and Xiong, 2008; Rico and Marin, 2011). The NRG1 and ERBB4 
genes were identified as major susceptibility genes for schizophrenia by many association 
studies in several ethnic groups (Liu et al., 2005; Nicodemus et al., 2010; Stefanis et al., 2013; 
Stefansson et al., 2002). Furthermore, impaired NRG1-ErbB4 signalling is associated with 
cortical dysfunction, cognitive deficits and schizophrenia symptoms (Harrison and Law, 2006; 
Iwakura and Nawa, 2013; Law et al., 2012; Mei and Xiong, 2008; Rico and Marin, 2011).   
 
Abnormal NRG1-ErbB4 signalling in various brain regions has been linked with 
schizophrenia in many studies. One study reported that NRG1 has been found to be involved 
in altering the size of the superior temporal gyrus in schizophrenia (Tosato et al., 2012). A 
number of post-mortem studies have examined the expression of NRG1 and ErbB4 in the 
brain of schizophrenia patients (Pan et al., 2011). For example, Hashimoto et al. reported an 
increase in the mRNA expression of the NRG1-type I isoform, and a decrease in the NRG1-
type II isoform in the prefrontal cortex (PFC) (Hashimoto et al., 2004). A study of elderly 
schizophrenia patients indicated that gene expression of the NRG1-type I isoform decreased 
in the PFC (Brodmann’s area 10, BA10), while expression of the NRG1-type II isoform 
increased in BA10 (Parlapani et al., 2010). Expression of NRG1-type I mRNA is also 





protein levels of the NRG1 intracellular part increased in the PFC of schizophrenia patients 
(Chong et al., 2008). Furthermore, post-mortem studies have shown that mRNA and protein 
expression of ErbB4 receptors is increased in the PFC of schizophrenia patients (Chong et al., 
2008; Law et al., 2007; Silberberg et al., 2006). Importantly, an elevated phosphorylation of 
ErbB4 receptors and enhanced activity of downstream signalling pathways have been 
reported in the PFC of schizophrenia patients (Hahn et al., 2006). Therefore, although the 
results from post-mortem studies are not completely consistent, evidence from the majority of 
studies implied an elevation in NRG1-ErbB4 signalling in schizophrenia (Hahn, 2011; Pan et 
al., 2011). In addition, the cingulate cortex (Cg) is also involved in the pathophysiology of 
schizophrenia (Natesan et al., 2006; Newell et al., 2006; Newell et al., 2005). A recent animal 
study indicated that mutation in the NRG1 transmembrane domain altered the expression of 
glutamatergic receptors in the Cg (Newell et al., 2013). 
 
To date, antipsychotic drugs have been widely used in the clinic to treat schizophrenia 
symptoms. It is interesting that schizophrenia patients with different NRG genotypes have 
been found to be able to respond differently to typical antipsychotics (Kampman et al., 2004). 
Haloperidol and clozapine have also been reported to improve the schizophrenia-like 
behaviour observed in Nrg1-/+ or ErbB4-/+ knockout mice (Dejaegere et al., 2008; Rimer et al., 
2005; Savonenko et al., 2008). These reports suggest that antipsychotic drugs may exert their 
therapeutic effects partially through the NRG1-ErbB4 signalling pathway. Several studies 
have investigated the effects of particular antipsychotics (haloperidol, clozapine and 
risperidone) on the expression of NRG1 and ErbB4 receptors in the brain, however, the 
results are inconsistent (Chana et al., 2009; Hahn et al., 2006; Wang et al., 2008). A key issue 
is that schizophrenia patients often undergo chronic, even life-time, antipsychotic treatment; 





the expression of NRG1 and ErbB4 receptors, particularly treatment with olanzapine and 
aripiprazole, whose effects have not previously been examined. To summarise, the present 
study has investigated the short- and long-term effects of three antipsychotics (haloperidol, 
olanzapine and aripiprazole) on the expression of NRG1 and ErbB4 receptors in the PFC, Cg, 
and hippocampus of rats.  
 
2. Methods 
2.1 Animals and drug treatment 
Female Sprague Dawley rats (220-250g) were obtained from the Animal Resource Centre 
(Perth, Australia). Rats were housed in individual cages under environmentally controlled 
conditions (temperature 22°C, light cycle from 07:00 to 19:00 h), with ad libitum access to 
water and a standard laboratory chow diet. After 1-week acclimatisation to the new 
surroundings, rats were randomly assigned to one of the following treatment groups: 
aripiprazole (0.75mg/kg, 3 times/day; Bristol-Meyers Squibb, USA), olanzapine (0.5mg/kg, 3 
times/day; Eli Lilly, USA), haloperidol (0.1mg/kg, 3 times/day; Sigma Aldrich, USA), or 
vehicle (control).  Each drug group was randomly subdivided into short-term (1 week, n = 6 
per group) and long-term (12 weeks, n = 6 per group) treatment groups. It is worthy of note 
that antipsychotics have a much shorter half-life in rats than in humans. For example, the 
half-life of olanzapine is 24.2 hours in plasma and 72 hours in the brain of humans (Tauscher 
et al., 2002), compared with 2.5 hours and 5.1 hours in the plasma and brain of rats, 
respectively (Aravagiri et al., 1999). Haloperidol’s plasma half-life is 14.5-36.7 hours in 
humans (de Leon et al., 2004), but 1.5 hours in rats (Cheng and Paalzow, 1992). Aripiprazole 
has a long plasma elimination half-life (60-70 hours) in humans (Grunder et al., 2008), while 
in rats aripiprazole reached the maximal plasma concentration (Cmax) 2 hours after oral 





Therefore, all rats were treated three times per day, at 06:00, 14:00, and 22:00 h, orally by 
administering specially prepared sweet cookie dough pellets (0.3g) to ensure a consistently 
high concentration to better mirror the human scenario of oral administration once per day 
(Deng et al., 2012; Han et al., 2008; Weston-Green et al., 2011). The rats were sacrificed 
using carbon dioxide asphyxiation 48 hours after the last drug treatment. All experimental 
procedures were approved by the Animal Ethics Committee, University of Wollongong, and 
complied with the Australian Code of Practice for the Care and Use of Animals for Scientific 
Purposes (Seventh Edition, 2004). 
 
2.2 Western blotting 
All rats were sacrificed between 07:00 and 09:00 hours to minimise possible circadian-
induced variation of protein expression. Brains were immediately removed, frozen in liquid 
nitrogen and stored at -80°C. Three sites of the brain (the PFC, Cg, and hippocampus) 
involved in the pathophysiology of schizophrenia and antipsychotic therapeutics (Ginovart 
and Kapur, 2012; Lewis and Gonzalez-Burgos, 2006; Newell et al., 2006; Newell et al., 2005; 
Volk et al., 2010) were dissected to detect NRG1 and ErbB4 protein expression. In addition, 
abnormal expression of NRG1 and ErbB4 has been identified in the PFC and hippocampus of 
schizophrenia patients (Chong et al., 2008; Law et al., 2006). In brief, 500m thickness fresh 
frozen brain was cut at -14ºC and collected on glass slides (Lian et al., 2014a, c; Zhang et al., 
2014). Identified using a standard rat brain atlas (Paxinos and Watson, 1997), the PFC 
(Bregma 4.68mm to 2.76mm), Cg (Bregma 2.28mm to -0.36mm) and hippocampus (Bregma 
-2.28mm to -5.40mm) were collected bilaterally using a microdissection puncher. Tissue 
obtained from individual rats was homogenised in ice-cold homogenising buffer [9.8ml NP-
40 cell lysis buffer (Invitrogen, Camarillo, CA, USA), 100µl β-Glycerophosphate (50mM; 





Inhibitor Cocktail (Sigma-Aldrich)]. The samples were centrifuged, and the supernatants 
were collected and stored at -80°C until required.  
 
Total protein concentrations were quantified spectrophotometrically using the Bio-Rad DC 
Protein Assay (500-0116, Bio-Rad, Hercules, CA, USA) at A750nm. A range of sample 
proteins (5, 10, 15, 20µg) were pre-tested, and 10µg of protein was selected because it best 
fitted the linear range of signal detection. Homogenised brain samples containing 10µg of 
protein were firstly heated at 95 °C in the loading buffer [950µl laemmli buffer (Bio-Rad) 
and 50µl β-mercaptoethanol (Sigma-Aldrich)] for five minutes to denature the protein. The 
samples were loaded into CRTGEL4-12% Bis-Tris Polyacrylamide Gels (Bio-Rad) and 
subjected to electrophoresis in 1x XT-MOPS running buffer [50ml 20x XT-MOPS running 
buffer (Bio-Rad) and 950ml distilled water] at 200V for 50 minutes. Proteins on the gels were 
then transferred electrophoretically onto a polyvinylidene difluoride (PVDF) membrane (Bio-
Rad) in the ice cold transfer buffer [150ml 10x Tris/Glycine Buffer (Bio-Rad), 300ml cold 
methanol and 1050ml distilled water] at 100V for one hour. To detect the proteins of interest, 
PVDF membranes were incubated in the Tris-Buffered Saline-Tween (TBST) (Sigma-
Aldrich) solution containing 5% BSA for one hour at room temperature, and then incubated 
overnight at 4°C with primary antibodies for NRG1 (1:200; SC-348 Santa Cruz 
Biotechnology, Santa Cruz, CA, USA) and ErbB4 (1:500; SC-283 Santa Cruz Biotechnology, 
Santa Cruz, CA, USA) diluted in TBST buffer containing 1% BSA. Membranes were washed 
three times with TBST for five minutes and incubated for one hour at room temperature with 
horseradish peroxidase-conjugated goat anti-rabbit (1:3000; Millipore, Temecula, CA, USA) 
secondary antibodies diluted in TBST buffer containing 1% BSA, and following 3 TBST 
washes, proteins of interest were visualised using an ECL system (GE Life Sciences, 





probed with mouse anti-actin primary polyclonal antibody (1:10000; Millipore, Temecula, 
CA) and horseradish peroxidase-conjugated rabbit anti-mouse secondary antibody (1:3000; 
Millipore, Temecula, CA).  
 
The immunoreactive signals were quantified by densitometry and the values were corrected 
based on their corresponding actin levels. For NRG1, the band of ~135kDa was quantified, as 
a likely full-length version of the NRG1 molecule (Kalinowski et al., 2010; Li et al., 2013). 
Bands of ~70kDa and ~40kDa were also quantified, which are most likely a reflection of 
altered processing / turnover of the NRG1 protein (Benvegnu et al., 2011; Lemmens et al., 
2011; Li et al., 2013). It is worth noting that similar isoforms have been identified in both 
humans and rodents (Steinthorsdottir et al., 2004). For ErbB4 the band of ~185kDa was 
detected, representing the full-length molecule of ErbB4 (du Bois et al., 2012; Li et al., 2013; 
Wang et al., 2008). To determine the specificity of the manufacturer’s antibody, membranes 
were pre-absorbed with corresponding antigen peptide, i.e. NRG1-β (SC-348, Santa Cruz 
Biotechnology, Santa Cruz, CA, USA) or ErbB4 (SC-283, Santa Cruz Biotechnology, Santa 
Cruz, CA, USA), prior to the Western blot experiments. These antibodies are recommended 
to detect NRG1 and ErbB4 of both humans and rodents. All bands that were analysed in the 
present study were eliminated, confirming that the bands quantified with the antibody 
represent NRG1 isoforms or ErbB4. The β-actin protein was quantified at 46kDa. All results 
were normalised by taking the value of the vehicle group as 100%. Each sample from all 
groups (n = 6 per group) has been run in quadruplicate for Western blotting assay to confirm 
the reliability of the results.  
 





All data was analysed using the SPSS 19.0 program (SPSS, Chicago, IL, USA) and expressed 
as mean ± S.E.M. The protein expression in each brain region was analysed by Kruskal-
Wallis H-test, followed by post-hoc comparisons between the control and drug treatment 
groups by a Mann-Whiney U-test. Statistical significance was accepted when p ≤ 0.05. 
 
3. Results  
3.1 Effects of short- and long-term antipsychotic treatment on the protein expression of 
NRG1 and ErbB4 receptors in the prefrontal cortex 
Figure 1 shows the changes in the protein levels of ErbB4 receptors (Figure 1B) and NRG1 
isoforms (Figures 1C and 1D) in the PFC after treatment with the three antipsychotics. One-
week treatment with haloperidol tended to up-regulate the NRG1-70kDa protein levels, but 
not reach significance (+40%, p = 0.076; Figure 1A and 1C), whereas 12-week treatment 
with haloperidol significantly decreased the level of NRG1-135kDa (40%, p < 0.05) and 
NRG1-40kDa (36%, p < 0.05) (Figure 1D). In addition, decreased protein levels of NRG1-
135kDa (58%, p < 0.01; Fig 1D), NGR1-70kDa (47%, p < 0.01) and NRG1-40kDa (42%, p < 
0.05) were observed in the 12-week aripiprazole group; however, no significant effects on 
NRG1 levels were revealed after short-term aripiprazole treatment (Figure 1C). Furthermore, 
12-week treatment with olanzapine significantly decreased the level of NRG1-40kDa (35%, p 
< 0.05; Figure 1D). 
 
The protein expression of ErbB4 in the PFC was significantly increased by 1-week treatment 
with haloperidol (+113%, p < 0.05; Figure 1B), while 1-week treatment with aripiprazole 
also increased ErbB4 receptors expression, but not significantly (+66%, p > 0.1). In addition, 
the expression of ErbB4 receptors was down-regulated by chronic treatment with aripiprazole 





treatment also induced a lower ErbB4 expression than the control group, although it did not 
reach significance (-33%, p > 0.1). 
 
3.2 Effects of short- and long-term antipsychotic treatment on the protein expression of 
NRG1 and ErbB4 receptors in the cingulate cortex 
Figure 2 shows the changes in the protein levels of ErbB4 receptors (Figure 2B) and NRG1 
isoforms (Figure 2C and 2D) in the Cg after treatment with the three antipsychotics. The 
results indicate that 12-week treatment with aripiprazole decreased protein levels of all three 
NRG1 isoforms (NRG1-70kDa: -45%, p < 0.05; NRG1-40kDa: -48%, p < 0.01; NRG1-
135kDa: -36%, p = 0.07, not significant; Figure 2D). Long-term treatment with both 
haloperidol and olanzapine significantly decreased the protein levels of the NRG1-40kDa (-
48%, p < 0.05 for haloperidol; -35%, p < 0.05 for olanzapine). However, no significant 
alteration in the expression of NRG1 isoforms was observed after 1-week treatment with all 
three antipsychotics (all p > 0.05; Figure 2C). In addition, neither 1-week nor 12-week 
treatment with all three antipsychotics had any significant effects (p > 0.1) on the expression 
of ErbB4 receptors in the Cg (Figure 2B).  
 
3.3 Effects of short- and long-term antipsychotic treatment on the protein expression of 
NRG1 and ErbB4 receptors in the hippocampus 
Figure 3 shows the changes in the expression of ErbB4 receptors (Figure 3B) and NRG1 
isoforms (Figure 3C and 3D) in the hippocampus after treatment with the three antipsychotics. 
It was revealed that 1-week treatment with haloperidol positively affected the protein levels 
of the NRG1-70kDa (+32%; p < 0.05) (Figure 3A and 3C). In addition, 1-week treatment 
with olanzapine significantly increased the protein levels of NRG1-70kDa (+67%, p = 0.05) 





significant decrease in the protein levels of NRG1-135kDa (-34%, p < 0.05), - 70kDa (-29%, 
p < 0.05) and a non-significant decrease in NRG1-40kDa (-32%, p = 0.06). Moreover, 12-
week treatment with haloperidol down-regulated the expression of NRG1-40kDa (-36%, p < 
0.05), whereas 12-week treatment with olanzapine showed no significant effect on the protein 
levels of all NRG1 isoforms.  
 
For the protein expression of the ErbB4 receptor, Figure 3B shows that there was a 
significant decline after 12-week treatment with both aripiprazole (-43%, p < 0.05) and 
haloperidol (-33%, p < 0.05). There were no significant changes in the expression of ErbB4 
in the hippocampus in the 1-week treatment groups, although there was a non-significant 
increase in the 1-week olanzapine treatment group (+54%, p > 0.1; Figure 3B). 
 
4. Discussion 
The present study is the first study that investigated the short- and long-term effects of 
olanzapine and aripiprazole treatment on the expression of NRG1 isoforms and ErbB4 
receptors. The present study demonstrated that the protein expression of NRG1 and ErbB4 
receptors was differentially affected by short- (1-week) and long-term (12-week) treatment 
with various antipsychotic drugs (Summarized in Table 1). Short-term treatment tended to 
increase the protein levels of NRG1 and ErbB4 receptors; in particular, short-term treatment 
with haloperidol increased the expression of NRG1-70kDa (not significant) and ErbB4 
receptors in the PFC, and NRG1-70kDa in the hippocampus, respectively. In addition, short-
term treatment with olanzapine induced a significant increase in the protein levels of NRG1-
70kDa in the hippocampus. In contrast, long-term treatment with these antipsychotics was 
able to decrease the protein levels of NRG1 isoforms and ErbB4 receptors. Long-term 





40kDa isoforms in the PFC, in NRG1-70kDa and -40kDa isoforms in the Cg, in NRG1-
135kDa and -70kDa isoforms in the hippocampus and in ErbB4 receptors in the PFC and the 
hippocampus. Long-term treatment with haloperidol significantly decreased the expression of 
NRG1-135kDa, -40kDa and ErbB4 receptors in the PFC, and NRG1-40kDa in the Cg and 
hippocampus. Long-term treatment with olanzapine did not show as many effects as the other 
two antipsychotics, only reducing the expression of NRG1-40kDa in the PFC and Cg. 
Together, these results indicated differential effects of antipsychotics on the expression of 
NRG1 and ErbB4 receptors in brain regions involved in the pathophysiology of 
schizophrenia. 
 
Several studies have investigated the effects of some antipsychotics on the expression of 
NRG1 and ErbB4 receptors, however, those results were discrepant (Chana et al., 2009; 
Shibuya et al., 2010; Wang et al., 2008; Zhang et al., 2008). A previous study found that 4-
week treatment with clozapine (10mg/kg, once/day, i.p.) reduced the protein expression of 
NRG1β in the rat PFC, and increased NRG1 and ErbB4 expression in the hippocampus 
(Wang et al., 2008), while 4-week treatment with risperidone (1mg/kg, once/day, i.p.) up-
regulated NRG1 and ErbB4 expression in the hippocampus, but had no effect on expression 
in the PFC of rats (Wang et al., 2008). An in vitro study demonstrated that exposure to 
clozapine (but not haloperidol) for three weeks promoted NRG1 protein expression in human 
fetal brain aggregates (Chana et al., 2009). Differential effects of antipsychotic treatment in 
the expression of NRG1 have also been observed in blood samples. For example, treatment 
with risperidone and quetiapine for 2 weeks caused an increase in NRG1 mRNA expression 
in peripheral blood lymphocytes obtained from first-onset antipsychotic-naive schizophrenia 
patients compared to baseline levels prior to antipsychotic therapies (Zhang et al., 2008). 





serum NRG1 protein levels in cynomolgus monkeys (Shibuya et al., 2010). The exact reasons 
for these discrepancies are unknown; however, considering the different treatment duration 
between those studies and the present study, a plausible explanation could be a time-
dependent effect of antipsychotic treatment on NRG1-ErbB4 signalling.  
 
An in vivo study has reported that 4-week treatment with haloperidol (1mg/kg, once/day; i.p.) 
increased the protein expression of NRG1β in the PFC, and both NRG1β and ErbB4 in the 
hippocampus of rats (Wang et al., 2008). In contrast, 12-week treatment with haloperidol 
(2mg/kg/day, Medisorb polymer implant) was reported to significantly reduce NRG1-induced 
ErbB4 activation in the PFC of mouse brains (Hahn et al., 2006). Consistent with these 
findings, the present study shows that 1-week haloperidol treatment increased protein 
expression of NRG1 and ErbB4 receptors, but generally reduced their expression after 12-
week treatment (although some data does not reach significance). Time-dependent effects 
have also been observed in NRG1-ErbB4 responses to olanzapine and aripiprazole treatment. 
For example, 1-week treatment with olanzapine increased the protein levels of NRG1 in the 
hippocampus, but had no effects in other brain regions; however, 12-week olanzapine 
treatment negatively affected NRG1-40kDa expression in the Cg, but did not reveal any other 
effects. On the other hand, although the expression of NRG1 and ErbB4 did not significantly 
changed after 1-week treatment with aripiprazole, their expression was decreased by 12-week 
aripiprazole treatment in all three brain areas to varying degrees. Together, the results of the 
present study suggest a general trend where short-term treatment with antipsychotics (up to 4 
weeks) may increase the expression of NRG1 and ErbB4 receptors, whereas prolonged 
antipsychotic treatment could decrease their expression. Although the mechanisms 
underlying the time-dependent effects of antipsychotics are unknown, an adaptive change 





2005). In view of the important roles of NRG1-ErbB4 signalling in 
neurotransmission/synaptic plasticity and the pathophysiology of schizophrenia (i.e. generally 
up-regulated NRG1-ErbB4 signalling in schizophrenia), these adaptations might contribute to 
the therapeutic effects of antipsychotics (Hyman and Nestler, 1996). 
 
Evidence from the present and previous studies indicates that antipsychotics might regulate 
NRG1-ErbB4 expression in a brain region-specific manner (Wang et al., 2008). The 
expression of NRG1-ErbB4 in the three brain regions examined in the present study 
displayed different responses following antipsychotic treatment, which might be due to the 
distinct neural circuits in these brain regions. The altered expression of NRG-ErbB4 in the 
PFC was more remarkable than in other brain regions in the present study. The functions of 
the PFC are intricately regulated by GABAergic and glutamatergic transmission that is 
affected by NRG-ErbB4 signalling (Woo et al., 2007). An in vivo study suggested that 
enhanced interaction among ErbB4, postsynaptic density-95 (PSD95) and N-methyl-D-
aspartate receptor (NMDAR) is associated with impairment of working memory in rats, 
inducing behavioural abnormalities (Li et al., 2013). A clinical study has reported switching 
to aripiprazole improved working memory in schizophrenia patients (Schlagenhauf et al., 
2010). In the present study, chronic treatment with aripiprazole displayed the strongest effects 
in reducing the expression of NRG1 isoforms and ErbB4 receptors among the three 
antipsychotics, which probably indicates that decreasing the interaction among ErbB4, 
PSD95 and NMDAR is one possible route for aripiprazole to improve the working memory. 
Therefore, the present study might add a new line of evidence that schizophrenia symptoms 
may be alleviated by aripiprazole by regulating NRG1-ErbB4 signalling in the PFC through 
antipsychotic treatment. Furthermore, clozapine and haloperidol could improve PPI (prepulse 





2008; Savonenko et al., 2008); therefore the effects of haloperidol on the expression of NRG1 
and ErbB4 observed in this study may provide a mechanism for this behavioural effect. 
However, further studies are important to investigate whether olanzapine and aripiprazole 
could improve PPI deficits in NRG1 and ErbB4 knock-out mice. 
 
Several post-mortem studies indicated that both protein and mRNA levels of NRG1 isoforms 
and ErbB4 receptors are over-expressed in various brain regions of schizophrenia patients 
(although discrepancies exist) (Chong et al., 2008; Hashimoto et al., 2004; Law et al., 2007; 
Parlapani et al., 2010; Silberberg et al., 2006; Weickert et al., 2012). Weickert and colleagues 
(2012) also stated that HapICE risk alleles induced an earlier age of onset by increasing the 
mRNA expression of NRG1-type III, which indicates that the increased expression of NRG1 
isoforms from post-mortem tissue is not a consequence of the disease or the drug treatment. 
In the present study, we found that long-term treatment with all three antipsychotics 
(especially aripiprazole and haloperidol) was able to reduce the protein expression of all three 
NRG1 isoforms and ErbB4 receptors, suggesting that inhibiting NRG1-ErbB4 expression is a 
possible route for antipsychotics to elicit their therapeutic effects although further studies are 
needed. 
 
Evidence from the present and previous studies reveals that various antipsychotics with 
various pharmacological binding profiles regulate NRG1-ErbB4 expression in distinct ways 
(Chana et al., 2009; Wang et al., 2008; Zhang et al., 2008). There is no evidence that 
antipsychotics could directly bind with ErbB4 receptors, although they do possess affinities 
for several G-protein coupled receptors (GPCRs), particularly dopamine D2 receptors and 
serotonin 5-HT receptors (Correll, 2010; Kapur and Mamo, 2003). For example, haloperidol 





potent dopamine D2 receptor antagonists, while aripiprazole acts as a partial agonist (Correll, 
2010) or a functionally selective ligand for the dopamine D2 receptor (Mailman and Murthy, 
2010). Additionally, olanzapine displays antagonism for serotonin 5-HT2A,2C receptors, which 
interacts with dopamine D2 receptor antagonism to achieve its clinical efficacy (Mathews and 
Muzina, 2007; Meltzer and Massey, 2011), while aripiprazole is a partial agonist of 5-HT1A 
receptors and an antagonist of 5-HT2A receptors (Jordan et al., 2002; Zhang et al., 2006). 
Therefore, the differential effects of various antipsychotic drugs on NRG1-ErbB4 expression 
might partly be related to their distinct pharmacological binding profiles (Deng et al., 2013). 
Furthermore, in view of the recent evidence that NRG1-ErbB4 signalling suppresses the Src 
tyrosine kinase-mediated increase in synaptic NMDA transmission (Pitcher et al., 2011), and 
that NRG1-ErbB4 signalling can activate Fyn and Pyk2 kinases leading to increased NMDA 
NR2B phosphorylation (Bjarnadottir et al., 2007), NMDA hypofunction observed in 
schizophrenia could be caused by either increased or decreased NRG1-ErbB4 signalling 
(Deng et al., 2013). Therefore, antipsychotic effects on NRG1-ErbB4 expression may 
contribute to schizophrenia therapy by modulating NMDA transmission via the Src or 
Fyn/Pyk2 pathways (Deng et al., 2013).  
 
One limitation of this study was that the plasma concentration of drugs was not measured 
during the experimental period. Antipsychotic dosages used in this study were chosen 
according to dosage translation between species based on body surface area following the 
FDA guideline (FDA, 2005; Reagan-Shaw et al., 2008). A 0.75mg/kg aripiprazole dosage in 
rats is equivalent to ~7.5mg in humans (60 kg body weight), while 0.5mg/kg olanzapine and 
0.1mg/kg haloperidol is equivalent to ~5mg and ~1mg respectively; all of which are within 
the used/recommended clinical dosages (Emsley, 2009). It is important that the drug dosages 





and behaviourally effective (Assié et al., 2006; Deng et al., 2007; Han et al., 2009a; Weston-
Green et al., 2011). It should also be noted that female rats were used in this study, because 
our previous studies have shown that female rats are a suitable model for investigating 
pharmacological effects of antipsychotics (Han et al., 2009a; Han et al., 2009b; Han et al., 
2008; Lian et al., 2013, 2014b; Matosin et al., 2013). Furthermore, rats were closely housed 
in a room occupied by only female rats in this study. Our pre-experiments have shown that, 
under this rearing condition, the estrus cycles of all female rats are synchronized (Lian et al., 
2013). It is also interesting that the NRG1-40kDa isoform was consistently affected by 
haloperidol and olanzapine, but not aripiprazole. This is mostly due to their different 
pharmacological profiles as discussed above, however the possibility of changes in stability 
of this peptide could not be completely excluded. Another limitation of this study is that only 
protein levels of NRG1 and ErbB4 were measured; it is important to confirm these results by 
examining mRNA expression using qPCR. 
 
In conclusion, the results from the present study demonstrated the time-dependent and 
region-specific effects of antipsychotics on NRG1 and ErbB4 receptor expression and 
signalling in rats. These changes might contribute to the efficacy of antipsychotics to treat 
schizophrenia. In future studies, it will be important to investigate whether antipsychotics 
have similar effects on NRG1-ErbB4 signalling and correlating behavioural responses in 
animal models for schizophrenia. In light of the fact that schizophrenia patients with different 
NRG genotypes respond differently to typical antipsychotics (Kampman et al., 2004), it is 
worth investigating whether schizophrenia patients with different NRG genotypes also 
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